On heels of adopting ‘poison pill’, Heat Bio recruits new scientific expertise

On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a “poison pill” for protection against hostile takeovers – Durham’s Heat Biologics (Nasdaq: HTBX) and its subsidiary Pelican Therapeutics have recruited some new scientific expertise.

Heat disclosed in a filing with the SEC on Monday that medical oncologist Dr. Anthony Tolcher has joined the respective scientific advisory boards of both Heat and Pelican.

Read more on The Triangle Business Journal.